RT Journal Article
T1 Short‐ and mid‐term morbidity and primary‐care burden due to infant respiratory syncytial virus infection: A Spanish 6‐year population‐based longitudinal study
A1 Ares Gómez, Sonia
A1 Mallah, Narmeen
A1 Salas Ellacuriaga, Antonio
A1 Martinón Torres, Federico
AB BackgroundThe morbidity burden of respiratory syncytial virus (RSV) in infants extends beyond hospitalization. Defining the RSV burden before implementing prophylaxis programs is essential for evaluating any potential impact on short- to mid-term morbidity and the utilization of primary healthcare (PHC) and emergency services (ES). We established this reference data using a population-based cohort approach.MethodsInfants hospitalized for RSV from January 2016 to March 2023 were matched with non-hospitalized ones based on birthdate and sex. We defined the exposure as severe RSV hospitalization. The main study outcomes were as follows: (1) PHC and ES visits for RSV, categorized using the International Classification of Primary Care codes, (2) prescriptions for respiratory airway obstructive disease, and (3) antibacterial prescriptions. Participants were followed up from 30 days before hospitalization for severe RSV until the outcome occurrence or end of the study. Adjusted incidence rate ratios (IRRs) of the outcomes along with their 95% confidence intervals (CI) were estimated using Poisson regression models. Stratified analyses by type of PHC visit (nurse, pediatrician, or pharmacy) and follow-up period were undertaken. We defined mid-term outcomes as those taking place up to 24 months of follow-up period.ResultsThe study included 6626 children (3313 RSV-hospitalized; 3313 non-hospitalized) with a median follow-up of 53.7 months (IQR = 27.9, 69.4). After a 3-month follow-up, severe RSV was associated with a considerable increase in PHC visits for wheezing/asthma (IRR = 4.31, 95% CI: 3.84–4.84), lower respiratory infections (IRR = 4.91, 95% CI: 4.34–5.58), and bronchiolitis (IRR = 4.68, 95% CI: 2.93–7.65). Severe RSV was also associated with more PHC visits for the pediatrician (IRR = 2.00, 95% CI: 1.96–2.05), nurse (IRR = 1.89, 95% CI: 1.75–1.92), hospital emergency (IRR = 2.39, 95% CI: 2.17–2.63), primary healthcare emergency (IRR: 1.54, 95% CI: 1.31–1.82), as well as with important increase in prescriptions for obstructive airway diseases (IRR = 5.98, 95% CI: 5.43–6.60) and antibacterials (IRR = 4.02, 95% CI: 3.38–4.81). All findings remained substantial until 2 years of post-infection.ConclusionsSevere RSV infection in infants significantly increases short- to mid-term respiratory morbidity leading to an escalation in healthcare utilization (PHC/ES attendance) and medication prescriptions for up to 2 years afterward. Our approach could be useful in assessing the impact and cost-effectiveness of RSV prevention programs.
PB Wiley
YR 2024
FD 2024
LK http://hdl.handle.net/10347/34649
UL http://hdl.handle.net/10347/34649
LA eng
NO Ares-Gómez S, Mallah N, Pardo-Seco J, et al. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study. Pediatr Allergy Immunol. 2024; 0:e14131. doi:10.1111/pai.14131
NO This work was supported by the Framework Partnership Agreementbetween the Consellería de Sanidad de la XUNTA de Galicia andGENVIP-IDIS-2021–2024 (SERGAS-IDIS March 2021; Spain). In ad-dition, it received support by (i) ISCIII: TRINEO: PI22/00162; DIAVIR:DTS19/00049; Resvi-Omics: PI19/01039 (to A.S.), ReSVinext: PI16/01569, Enterogen: PI19/01090, OMI-COVI-VAC: PI22/00406(to F.M.-T.), cofinanciados FEDER, (ii) GAIN: IN607B 2020/08and IN607A 2023/02 (to A.S.), GEN-COVID IN845D 2020/23 (toF.M.-T.), IIN607A2021/05 (to F.M.-T.); (iii) ACIS: BI-BACVIR (PRIS-3, to A.S.), CovidPhy (SA 304 C, to A.S.); and (iv) consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias(CB21/06/00103; to A.S. and F.M.-T.). The NIRSE-GAL study (CEIC2023–377) is funded by Sanofi Pasteur/AstraZeneca through a research grant to the Healthcare Research Institute of Santiago.
DS Minerva
RD 28 abr 2026